Management and prevention of cytomegalovirus infection after renal transplantation (Q35235567)

7 August 2017

1 reference

title

Management and prevention of cytomegalovirus infection after renal transplantation (English)

1 reference

7 August 2017

0 references

cytomegaloviral disease

1 reference

E. Farrugia

1

1 reference

PubMed ID

1331630

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1331630

14 September 2022

T. R. Schwab

series ordinal

2

1 reference

PubMed ID

1331630

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1331630

14 September 2022

language of work or name

English

0 references

publication date

1 September 1992

1 reference

7 August 2017

12

1 reference

inferred from page(s)

published in

Mayo Clin Proc

1 reference

7 August 2017

67

1 reference

7 August 2017

9

1 reference

7 August 2017

879-890

1 reference

Cytomegalovirus infection after renal transplantation

7 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Cytomegalovirus Infections Following Renal Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

The prevention of cytomegalovirus disease in renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Cytomegalovirus infection and renal transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Multicenter seroepidemiologic study of the impact of cytomegalovirus infection on renal transplantation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Acquisition of donor strains of cytomegalovirus by renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Symptomatic cytomegalovirus infection in seropositive kidney recipients: reinfection with donor virus rather than reactivation of recipient virus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Treatment of invasive cytomegalovirus disease in solid organ transplant patients with ganciclovir

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Febrile reactions to pneumococcal vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Comparison of culture and serology for the diagnosis of cytomegalovirus infection in kidney and liver transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Virus-Specific IgG and IgM Antibodies in Normal and Immunocompromised Subjects Infected with Cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Diagnosis of cytomegalovirus infection in cyclosporin-treated renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Cytomegalovirus-specific antibodies to an immediate early antigen and a late membrane antigen and their possible role in controlling secondary cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Antibody response to the immediate early protein of cytomegalovirus in renal transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Immunoglobulin G subclasses and lymphocyte stimulatory responses to cytomegalovirus in transplant patients with primary cytomegalovirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Use of monoclonal antibodies for the diagnosis of cytomegalovirus infection by the detection of early antigen fluorescent foci (DEAFF) in cell culture

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Rapid detection of human cytomegalovirus DNA in peripheral blood leukocytes of viremic transplant recipients by the polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Cytomegalovirus infection of renal allografts. Detection by polymerase chain reaction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Suppression of natural killer cell activity and T cell proliferation by fresh isolates of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Association of Herpesvirus Infections with T-Lymphocyte-Subset Alterations, Glomerulopathy, and Opportunistic Infections after Renal Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Diagnosis and Treatment of Cytomegalovirus Disease in Transplant Patients Based on Gastrointestinal Tract Manifestations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Detection of CMV DNA and CMV antigen in renal allograft biopsies by in situ hybridisation and immunohistochemistry

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Glomerulopathy Associated with Cytomegalovirus Viremia in Renal Allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Cytomegalovirus glomerulopathy: a controversial lesion

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Serological responses to cytomegalovirus during renal transplant rejection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Ganciclovir. A review of its antiviral activity, pharmacokinetic properties and therapeutic efficacy in cytomegalovirus infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Efficacy of ganciclovir in liver and kidney transplant recipients with severe cytomegalovirus infection.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Successful treatment of renal allograft rejection in the presence of cytomegalovirus disease. A report of two cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Pharmacokinetics of ganciclovir in a patient undergoing hemodialysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Polymerase chain reaction to evaluate antiviral therapy for cytomegalovirus disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Monitoring of human cytomegalovirus infections and ganciclovir treatment in heart transplant recipients by determination of viremia, antigenemia, and DNAemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Progressive disease due to ganciclovir-resistant cytomegalovirus in immunocompromised patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

A Randomized, Controlled Trial of Foscarnet in the Treatment of Cytomegalovirus Retinitis in Patients with AIDS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Intravenous foscarnet for the treatment of severe cytomegalovirus infection in allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Foscarnet nephrotoxicity: mechanism, incidence and prevention

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Ganciclovir for the treatment of cytomegalovirus gastroenteritis in bone marrow transplant patients. A randomized, placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Synergistic effect of ganciclovir and foscarnet on cytomegalovirus replication in vitro

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Isolation of Foscarnet-Resistant Human Cytomegalovirus Patterns of Resistance and Sensitivity to Other Antiviral Drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Human Monoclonal Antibodies Neutralizing Cytomegalovirus (CMV) for Prophylaxis of CMV Disease: Report of a Phase I Trial in Bone Marrow Transplant Recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Reducing the Risk for Transfusion-transmitted Cytomegalovirus Infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Effect of Towne live virus vaccine on cytomegalovirus disease after renal transplant. A controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

The status of cytomegalovirus vaccine.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Which renal transplant patients should receive cytomegalovirus immune globulin? A cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

A Randomized, Placebo-Controlled Trial of Oral Acyclovir for the Prevention of Cytomegalovirus Disease in Recipients of Renal Allografts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Pharmacologic basis for high-dose oral acyclovir prophylaxis of cytomegalovirus disease in renal allograft recipients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

A Controlled Trial of Ganciclovir to Prevent Cytomegalovirus Disease after Heart Transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Preemptive Therapy in Immunocompromised Hosts

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

A randomized, controlled trial of prophylactic ganciclovir for cytomegalovirus pulmonary infection in recipients of allogeneic bone marrow transplants; The City of Hope-Stanford-Syntex CMV Study Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Early treatment with ganciclovir to prevent cytomegalovirus disease after allogeneic bone marrow transplantation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

Regulation and tissue-specific expression of human cytomegalovirus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Donor seropositivity and prednisolone therapy as risk factors for cytomegalovirus infection and disease in cyclosporin-treated renal allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Early detection of active cytomegalovirus (CMV) infection after heart and kidney transplantation by testing for immediate early antigenemia and influence of cellular immunity on the occurrence of CMV infection

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Comparison of immunoblotting with other serological methods and virus isolation for the early detection of primary cytomegalovirus infection in allograft recipients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Detection of cytomegalovirus infections in specimens other than urine by the shell vial assay and conventional tube cell cultures

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Rapid detection of cytomegalovirus DNA and RNA in blood of renal transplant patients by in vitro enzymatic amplification

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Quo vadis? The clinical dilemma of simultaneous cytomegalovirus infection and steroid-resistant rejection

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Cytotoxic T cells specific for cytomegalovirus: a potential therapy for immunocompromised patients

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

Symptomatic cytomegalovirus disease in the cytomegalovirus antibody seropositive renal transplant recipient treated with OKT3.

1 reference

https://api.crossref.org/works/10.1016%2FS0025-6196%2812%2960828-3

7 January 2021

10.1016/S0025-6196(12)60828-3

Identifiers

DOI

1 reference

7 August 2017

1 reference

PubMed ID

1331630